All In Biotech

Drug Trial Radar · NCT06742333

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? Prospective Multicenter Interventional Study

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 22, 2025

Primary completion

Jul 22, 2028

Study completion Jan 1, 2029

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psoriasis is a chronic inflammatory condition driven by a complex interplay between heritable and microenvironmental factors. Genome-wide heritability for psoriasis (PsO) is estimated at up to 50%. Although bearing genetic susceptibility at birth, most patients will remain disease free for years until an exposomal trigger activates the immunological pathway that leads to the first disease flare. In rare patients, the first flare is an isolated event, but in most patients it will evolve into a chronically relapsing-remitting disease characterized by lasting lesions and recurrent flares. Primary objective is to compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24. Patients will be randomized 1:1 to receive either 320mg bimekizumab at weeks 0 (W0), W4, W8 and W12, or clobetasol ointment for 2 to 4 weeks until complete clearance of the lesion. After a maximum of 4 weeks topical clobetasol will be applied twice weekly on the site of lesion until week 16 then stopped. Patients will not receive active treatment between week 16-24. Between week 24-96 patients that flare can receive continuous topical clobetasol if needed. These patients will be considered non-responders at subsequent timepoints for the main analysis. If the patients worsen their psoriasis under the treatments given during the study and progress to moderate or severe psoriasis (PASI 10 and above) they will end their participation to the study to receive a treatment adapted to the new severity of their psoriasis. The patients will be referred to their dermatologist to receive the actual standard of care adapted to their new condition. During the study, the following assessments will be performed and samples will be collected

Conditions

  • Psoriasis

Interventions

  • BimekizumabDrug

    Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12

  • ClobetasolDrug

    Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of bimekizumab versus topical corticosteroids on psoriasisTime frame: at 24 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Edouard Herriot

    Lyon, France · Recruiting

  • Hôpital Saint-Joseph

    Marseille, France · Recruiting

  • Cabinet Dermatologie Dr RUER

    Martigues, France · Recruiting

  • CHU Saint-Etienne

    Saint-Etienne, France · Recruiting

  • CHITS

    Toulon, France · Recruiting

  • Médipole Villeurbanne

    Villeurbanne, France · Enrolling by invitation

  • CHU de Nice - Hôpital de l'Archet

    Nice, Alpes-Maritimes, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.